Distribution of IFIs in patients with haematological malignancies

'Risk stratification helps identify the patients likely to suffer from invasive aspergillosis, even if they do not present the classical risk factors, as defined in the guidelines or clinical trials.’ 2

  • During one of the largest epidemiology studies evaluating the incidence of IFIs in Europe, 92% (2,773/3,012) of patients with AML did not develop a mould infection1
  • Aspergillus species was the most common cause of mould infection1
  • Knowing which patients are at risk of developing invasive aspergillosis may aid early diagnosis and initiation of appropriate antifungal therapy1

Stratification of Risk Factors

Adapted from Herbrecht et al, 20122
Key: GvHD, graft versus host disease; HEPA, high-efficiency particulate air; HSCT, haematopoietic stem cell transplant; IA, invasive aspergillosis; ROS, reactive oxygen species.

  • Consideration needs to be given to:2
    • multiplicity of risk factors
    • synergy between different risk factors
  • Correct identification of the main risk factors for developing an IFD is essential in the evaluation of immunocompromised patients – and allows timely institution of appropriate antifungal therapy3
Voriconazole (Vfend®): for efficacy, patient outcomes4–6 and potential medium-term budgetary implications

 

IA, invasive aspergillosis; IFD, invasive fungal disease; IFI, invasive fungal infection

References
1. Pagano L, et al. Haematologica. 2006; 91: 1068–75.
2. Herbrecht R, et al. Ann N Y Acad Sci. 2012; 1272: 23–30.
3. Pagano L, et alJ Antimicrob Chemother. 2011; 66(Suppl 1): i5–14.
4. Vfend® Summary of Product Characteristics.
5. Marks DI, et al.  Br J Haematol. 2011; 155(3): 318–27.
6. Herbrecht R, et al. N Engl J Med. 2002; 347(6): 408–15.

 

Date of Preparation: June 2017

PP-VFE-GBR-0050

 

Prescribing Information

Vfend® (voriconazole) – SPC 
Legal Category: POM      Basic NHS Cost: Pack of 28 50 mg tablets £275.68, Pack of 28 200 mg tablets £1,102.74, 30 ml vial of 200 mg powder for intravenous infusion £77.14, 30 ml vial of 200 mg powder for intravenous infusion with 50 ml bag containing Vfend solvent for solution for infusion £77.14, 100 ml bottle of 40 mg/ml powder for oral suspension £551.37

Diflucan® (fluconazole) 10 mg/ml powder for oral suspension – SPC  
Legal Category: POM      Basic NHS Cost: Diflucan powder for oral suspension 10 mg/ml £16.61 

Diflucan® (fluconazole) 150 mg Capsules – SPC  
Legal Category: POM      Basic NHS cost: Diflucan hard capsules 150 mg £7.12

Diflucan® (fluconazole) 2 mg/ml solution for infusion – SPC  
Legal Category: POM      Basic NHS cost: Diflucan 2 mg/ml solution for infusion 100 ml £29.28

Diflucan® (fluconazole) 200 mg hard capsules – SPC  
Legal Category: POM      Basic NHS cost: Diflucan hard capsules 200 mg £66.42

Diflucan® (fluconazole) 40 mg/ml powder for oral suspension – SPC  
Legal Category: POM      Basic NHS cost: Diflucan powder for oral suspension 40 mg/ml £66.42

Diflucan® (fluconazole) 50 mg hard capsules – SPC  
Legal Category: POM      Basic NHS cost: Diflucan hard capsules 50 mg £16.61